乳腺癌新辅助化疗后残余肿瘤负荷与长期生存结局:5161例患者的多中心汇总分析
该汇总分析纳入欧洲和美国12个机构或试验的5161例I-III期乳腺癌患者,评估新辅助化疗后残余肿瘤负荷(RCB)评分与无事件生存的关系。RCB评分在各分子亚型中均为预后因素,校正后HR从激素受体阳性/HER2阴性组的1.52至激素受体阴性/HER2阳性组的2.09。作者认为RCB评分和分级在所有亚型中独立预后,可推广至多种实践环境。
要点
- RCB评分在各乳腺癌亚型中均与无事件生存显著相关,评分越高预后越差。
- 单变量HR从激素受体阳性/HER2阴性组的1.55至激素受体阴性/HER2阳性组的2.16。
- 校正年龄、分级、T分期和淋巴结状态后,RCB评分仍为独立预后因素。
核心结论
- RCB评分和分级在所有乳腺癌亚型中均为独立预后因素,并可推广至多种实践环境。
- 作者认为,前瞻性评估RCB可考虑纳入新辅助治疗后的标准病理报告。
研究设计与样本
- 汇总分析,纳入欧洲和美国12个机构或试验的5161例I-III期乳腺癌患者。
- 患者年龄≥18岁,接受新辅助化疗后手术,治疗时间为1994年9月12日至2019年2月11日。
- 采用混合效应Cox模型分析连续RCB评分与无事件生存的关系,纳入随机RCB和队列效应,并按激素受体状态和HER2状态分层。
主要发现
- 中位年龄49岁(IQR 20-80),随访期间发生1164例无事件生存事件,中位随访56个月(IQR 0-186)。
- 单变量分析中,RCB评分每增加一个单位,激素受体阳性/HER2阴性组HR为1.55(95%CI 1.41-1.71),激素受体阴性/HER2阳性组HR为2.16(95%CI 1.79-2.61),所有亚型P<0.0001。
- 多变量分析中,校正年龄、分级、T分期和基线淋巴结状态后,激素受体阳性/HER2阴性组校正HR为1.52(95%CI 1.36-1.69),激素受体阴性/HER2阳性组校正HR为2.09(95%CI 1.73-2.53),所有亚型P<0.0001。
关键数值与推荐
- RCB评分每增加一个单位,单变量HR从激素受体阳性/HER2阴性组的1.55(95%CI 1.41-1.71)至激素受体阴性/HER2阳性组的2.16(95%CI 1.79-2.61)(所有亚型P<0.0001)。
- 校正年龄、分级、T分期和基线淋巴结状态后,RCB评分每增加一个单位,校正HR从激素受体阳性/HER2阴性组的1.52(95%CI 1.36-1.69)至激素受体阴性/HER2阳性组的2.09(95%CI 1.73-2.53)(所有亚型P<0.0001)。
临床怎么用
- 作者认为,前瞻性评估RCB可考虑纳入新辅助治疗后的标准病理报告。
局限性
- 激素受体亚型定义和患者治疗存在变异性,可能影响预后性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in a broad range of practice settings. METHODS: In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I-III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We assessed the association between the continuous RCB score and the primary study outcome, event-free survival, using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years were computed for each RCB class within each subtype. FINDINGS: We analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20-80). 1164 event-free survival events occurred during follow-up (median follow-up 56 months [IQR 0-186]). RCB score was prognostic within each breast cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41-1·71) for hormone receptor-positive, HER2-negative patients to 2·16 (1·79-2·61) for the hormone receptor-negative, HER2-positive group (with or without HER2-targeted therapy; p<0·0001 for all subtypes). RCB score remained prognostic for event-free survival in multivariable models adjusted for age, grade, T category, and nodal status at baseline: the adjusted HR ranged from 1·52 (1·36-1·69) in the hormone receptor-positive, HER2-negative group to 2·09 (1·73-2·53) in the hormone receptor-negative, HER2-positive group (p<0·0001 for all subtypes). INTERPRETATION: RCB score and class were independently prognostic in all subtypes of breast cancer, and generalisable to multiple practice settings. Although variability in hormone receptor subtype definitions and treatment across patients are likely to affect prognostic performance, the association we observed between RCB and a patient's residual risk suggests that prospective evaluation of RCB could be considered to become part of standard pathology reporting after neoadjuvant therapy. FUNDING: National Cancer Institute at the US National Institutes of Health.
引用
- Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021. PMID: 34902335. doi:10.1016/S1470-2045(21)00589-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。